Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 23Carcinoma, Non-Small-Cell Lung 21Fallopian Tube Neoplasms 16Ovarian Neoplasms 14Triple Negative Breast Neoplasms 9Lung Neoplasms 9Brenner Tumor 9Breast Neoplasms, Male 9Adenocarcinoma of Lung 9Adenocarcinoma, Bronchiolo-Alveolar 8Unspecified Adult Solid Tumor, Protocol Specific 7Endometrial Neoplasms 7Neoplasm Metastasis 6Carcinoma, Ovarian Epithelial 6Melanoma 5Pancreatic Neoplasms 4Uterine Cervical Neoplasms 3Esophageal Neoplasms 3Carcinoma, Transitional Cell 3Adenocarcinoma Of Esophagus 3Urinary Bladder Neoplasms 2Platinum-Refractory Fallopian Tube Carcinoma 2Oropharyngeal Neoplasms 2Endometrial Adenocarcinoma 2Carcinoma 2Waldenstrom Macroglobulinemia 1Uveal Melanoma 1Thyroid Carcinoma, Anaplastic 1Testicular Neoplasms 1Stomach Neoplasms 1

Interventions

trastuzumab biosimilar HLX02 1Trastuzumab 1Taxes 1Radiotherapy 1Radiation 1Paclitaxel 1PF-05280014 1Ontruzant 1Ogivri 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Bladder Urothelial Carcinoma × Taxes × Clear all
NCT00238420 2022-07-19

Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
70 enrolled 10 charts
Genitourinary

Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡